Patents Assigned to PT. Dexa Medica
-
Patent number: 10688146Abstract: A preparation comprises a herbal extract and/or fraction, and a pharmaceutical preparation includes extract of Curcuma mangga Val. et Zipp., which has bioactivities in reducing expression levels of 5-alpha-reductase-1, androgen receptor, and PI3 in prostate cancer cells. The use of this present invention is directed to reduce prostate enlargement. Moreover, it also can be used to treat prostate cancer, lung cancer, and other diseases related to GPCR pathway.Type: GrantFiled: May 21, 2018Date of Patent: June 23, 2020Assignee: PT Dexa MedicaInventors: Asep Aripin, Agung Heru Karsono, Olivia Mayasari, Priska Hardadi, James M. Sinambela, Raymond R. Tjandrawinata
-
Publication number: 20180264070Abstract: A preparation comprises a herbal extract and/or fraction, and a pharmaceutical preparation includes extract of Curcuma mangga Val. et Zipp., which has bioactivities in reducing expression levels of 5-alpha-reductase-1, androgen receptor, and PI3 in prostate cancer cells. The use of this present invention is directed to reduce prostate enlargement. Moreover, it also can be used to treat prostate cancer, lung cancer, and other diseases related to GPCR pathway.Type: ApplicationFiled: May 21, 2018Publication date: September 20, 2018Applicant: PT DEXA MEDICAInventors: Asep Aripin, Agung Heru Karsono, Olivia Mayasari, Priska Hardadi, James M. SINAMBELA, Raymond R. TJANDRAWINATA
-
Publication number: 20170128513Abstract: Extract and/or fraction from Cinnamomum burmanii (DLBS2411) related to its extraction method and its biological activities show activities as antiulcer by conferring mucoprotection and down-regulating H+/KT+ ATPase. Treatment with DLBS2411 decreases the H+/K+ ATPase mRNA level in HEK 293 and gastric parietal cells. In addition, DLBS2411 inhibits activity of H+/K+ ATPase gastric enzyme wherein pH influences this inhibition mechanism. DLBS2411 also has characteristic as antioxidant which is shown by the increase of reducing power as the given dosage increases.Type: ApplicationFiled: October 19, 2016Publication date: May 11, 2017Applicant: PT. DEXA MEDICAInventors: POPPY FIRZANI ARIFIN, DEASY DIAH DWI RETNO WULAN, VERONIKA YULIANI, JAMES M. SINAMBELA, RAYMOND R. TJANDRAWINATA
-
Patent number: 9345731Abstract: A herbal extract composition from Lythraceae and Lauraceae family plants and its usage as insulin resistance reducer, syndrome X normalization, pre-diabetes and type 2 diabetes treatments, particularly as activator in insulin signal pathway, as modulator in glucose transport system, as modulator in adiponectin secretion, and as suppressor in insulin resistance. Representative from Lythraceae family has been selected Lagerstroemia speciosa, and representative from Lauraceae family has been selected Cinnamomum burmannii. Such herbal extract composition work synergistically to strengthen pharmacological effect produced by each extract if they act alone.Type: GrantFiled: August 4, 2009Date of Patent: May 24, 2016Assignee: PT. DEXA MEDICAInventors: Raymond R. Tjandrawinata, James M. Sinambela, Olivia Mayasari, Deasy Diah Dwi R. W., Melissa Puspasari
-
Patent number: 9131723Abstract: A pharmaceutical composition comprising a substantially coumarin-free extract derived from cinnamon. Its production method including some steps: grinding the raw material, extracting raw material from previous step by maceration using a first solvent to obtain crude extract of Cinnamomum burmanii, fractionating the extracted raw material from previous step through liquid-liquid extraction using a second solvent, wherein the second solvent is immiscible with the first solvent to obtain substantially coumarin-free extract, and optionally drying the substantially coumarin-free extract. The pharmaceutical composition comprising the substantially coumarin-free extract as a single component or in a combination with suitable pharmaceutical excipient(s) to produce a pharmaceutical composition that is safe to be consumed daily and in long-term use.Type: GrantFiled: November 23, 2010Date of Patent: September 15, 2015Assignee: PT. DEXA MEDICAInventors: James M. Sinambela, Veronika Yuliani, Deasy Diah Dwi Retno Wulan, Raymond R. Tjandrawinata
-
Patent number: 9078917Abstract: A pharmaceutical dosage form comprising an extract of Phaleria macrocarpa which has antineoplastic, anti-inflammatory, and antiangiogenic activity. Its use as an antineoplastic agent is to inhibit tumour growth. Its use as an anti-inflammatory agent is to relieve inflammation and pain, and also as an antipyretic. Another use is as an antiangiogenic agent to inhibit the growth of new blood vessels to prevent cancer metastasis.Type: GrantFiled: June 8, 2009Date of Patent: July 14, 2015Assignee: PT. Dexa MedicaInventors: Raymond R. Tjandrawinata, Asep Aripin, Poppy Firzani Arifin, Dina Rahmi
-
Patent number: 8999404Abstract: An extract and/or herbal fraction and pharmaceutical preparation include extract of Phaleria macrocarpa which for the purpose of this invention, is referred to as DLBS1449. The herbal extract according to the teaching of this invention is effectively applicable to inhibit the expression and activity of Cholesteryl Ester Transferase Protein (CETP), increase HDL cholesterol level, decrease LDL cholesterol level without raising blood pressure therefore it is further applicable in atherosclerosis therapy.Type: GrantFiled: April 19, 2012Date of Patent: April 7, 2015Assignee: Pt. Dexa MedicaInventors: Dwi Anggun Septiana Suciptan, Asep Aripin, Raymond R. Tjandrawinata
-
Publication number: 20140099392Abstract: An extract and/or herbal fraction and pharmaceutical preparation include extract of Phaleria macrocarpa which for the purpose of this invention, is referred to as DLBS1449. The herbal extract according to the teaching of this invention is effectively applicable to inhibit the expression and activity of Cholesteryl Ester Transferase Protein (CETP), increase HDL cholesterol level, decrease LDL cholesterol level without raising blood pressure therefore it is further applicable in atherosclerosis therapy.Type: ApplicationFiled: April 19, 2012Publication date: April 10, 2014Applicant: PT DEXA MEDICAInventors: Dwi Anggun Septiana Suciptan, Asep Aripin, Raymond R. Tjandrawinata
-
Publication number: 20140079820Abstract: Extract and/or fraction from Cinnamomum burmanii (DLBS2411) related to its extraction method and its biological activities show activities as antiulcer by conferring mucoprotection and down-regulating H+/K+ ATPase. Treatment with DLBS2411 decreases the H+/K+ ATPase mRNA level in HEK 293 and gastric parietal cells. In addition, DLBS2411 inhibits activity of H+/K+ ATPase gastric enzyme wherein pH influences this inhibition mechanism. DLBS2411 also has characteristic as antioxidant which is shown by the increase of reducing power as the given dosage increases.Type: ApplicationFiled: March 9, 2012Publication date: March 20, 2014Applicant: PT. DEXA MEDICAInventors: Poppy Firzani Arifin, Deasy Diah Dwi R.W., Veronika Yuliani, James M. Sinambela, Raymond R. Tjandrawinata
-
Publication number: 20130344181Abstract: A pharmaceutical composition comprising a substantially coumarin-free extract derived from cinnamon. Its production method including some steps: grinding the raw material, extracting raw material from previous step by maceration using a first solvent to obtain crude extract of Cinnamomum burmanii, fractionating the extracted raw material from previous step through liquid-liquid extraction using a second solvent, wherein the second solvent is immiscible with the first solvent to obtain substantially coumarin-free extract, and optionally drying the substantially coumarin-free extract. The pharmaceutical composition comprising the substantially coumarin-free extract as a single component or in a combination with suitable pharmaceutical excipient(s) to produce a pharmaceutical composition that is safe to be consumed daily and in long-term use.Type: ApplicationFiled: November 23, 2010Publication date: December 26, 2013Applicant: PT. DEXA MEDICAInventors: James M. Sinambela, Veronika Yuliani, Deasy Diah Dwi R.W., Raymond R. Tjandrawinata
-
Patent number: 8569382Abstract: The invention concerns compounds DLBS1425E2.2 and DLBS1425F1 isolated and identified from the extract of the plant Phaleria macrocarpa (Scheff.) Boerl. The invention also relates to the use of said compounds, either as a single active compound or in combination, in a pharmaceutical dosage form that has anti-proliferative activity of cancer cells, and its use relating to female related diseases. Formula (I).Type: GrantFiled: November 26, 2009Date of Patent: October 29, 2013Assignee: PT. Dexa MedicaInventors: Asep Aripin, Poppy Firzani Arifin, Raymond R. Tjandrawinata